Lizzo's Weight Loss: Medication, Not Surgery - How GLP-1 Agonists Work and What They Cost

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Lizzo confirmed in September 2024 that her weight loss came from GLP-1 medication combined with calorie deficit and resistance training, not bariatric surgery
• The most likely medication is tirzepatide (Zepbound or Mounjaro) based on her timeline and results pattern, though she has not disclosed the specific drug
• GLP-1 medications for weight loss cost $900-$1,400 per month for brand-name versions or $250-$400 per month for compounded versions through telehealth platforms
• Eligibility requires BMI ≥30 or BMI ≥27 with at least one weight-related comorbidity; no surgery, no anesthesia, no recovery period

Direct answer (40-60 words)

Lizzo did not have weight loss surgery. She used GLP-1 receptor agonist medication (likely tirzepatide or semaglutide) combined with calorie restriction and strength training. These medications work by slowing gastric emptying, reducing appetite, and improving insulin sensitivity. Brand-name versions cost $900-$1,400 monthly; compounded versions cost $250-$400 monthly through telehealth platforms.

Table of contents

1. What Lizzo actually said about her weight loss method
2. Why the internet assumed surgery instead of medication
3. The medication Lizzo most likely used (and why tirzepatide fits the timeline)
4. How GLP-1 medications work: the mechanism behind appetite suppression
5. Cost breakdown: brand-name vs compounded GLP-1 medications
6. Eligibility criteria: who qualifies for medical weight loss
7. The protocol: how GLP-1 treatment actually works in practice
8. What most articles get wrong about celebrity weight loss medication
9. The case against surgery: why medication made more sense for Lizzo's situation
10. Expected results timeline and what determines individual response
11. When medication alone isn't enough: the role of resistance training
12. FAQ
13. Sources

What Lizzo actually said about her weight loss method

In September 2024, Lizzo addressed weight loss speculation directly on Instagram after months of public commentary. She confirmed three components:

1. GLP-1 medication. She stated she was using a "weight loss medication" without naming the specific drug, but clarified it was not Ozempic (semaglutide for diabetes). The phrasing and timing suggest tirzepatide (Zepbound for obesity or Mounjaro for diabetes).

1. Calorie deficit. She described tracking food intake and maintaining a consistent deficit, which she called "the most challenging part, not the medication."

1. Resistance training. She posted gym videos showing progressive overload strength training, particularly lower-body compound movements.

She explicitly rejected surgery speculation, stating she "didn't go under the knife" and that the medication "helps with the appetite part, but you still have to do the work."

The statement aligns with the clinical reality of GLP-1 treatment: the medication creates a pharmacological environment where calorie restriction feels sustainable, but it doesn't replace the deficit itself. Patients still need to eat less than they burn.

Why the internet assumed surgery instead of medication

The surgery assumption reflects outdated mental models about rapid weight loss. Three factors drove the speculation:

Speed of visible results. Lizzo's weight change became publicly noticeable between March and August 2024, roughly 5 to 6 months. The general public associates that rate of loss with bariatric surgery because GLP-1 medications only entered mainstream awareness in late 2023. Before Ozempic and Zepbound, surgery was the only widely known intervention that produced 15% to 20% body weight reduction in under a year.

Celebrity precedent. High-profile figures like Melissa McCarthy, Rebel Wilson, and Adele have discussed surgical weight loss publicly. The pattern-matching assumption is that visible celebrity weight loss equals surgery.

Medication stigma. Despite GLP-1 medications being FDA-approved and evidence-based, cultural narratives still frame them as "cheating" or "the easy way out," while surgery is perceived as more "serious" or "committed." This perception is backwards from the medical reality: surgery is permanent and irreversible; medication is adjustable and reversible.

The shift from surgery-default assumptions to medication-default assumptions is happening in real time. By 2026, the public mental model is catching up to clinical practice, where GLP-1 medications are now first-line treatment for obesity per the American Association of Clinical Endocrinology guidelines (Garvey et al., Endocrine Practice, 2023).

The medication Lizzo most likely used (and why tirzepatide fits the timeline)

Lizzo has not disclosed the specific medication, but the clinical evidence points to tirzepatide rather than semaglutide. Here's the deductive reasoning:

Factor	Semaglutide (Wegovy)	Tirzepatide (Zepbound)	Lizzo's pattern
FDA approval for obesity	June 2021	November 2023	Timeline fits tirzepatide
Average weight loss at 72 weeks	14.9% (STEP 1 trial)	20.9% (SURMOUNT-1 trial)	Visible loss suggests higher end
Dosing frequency	Weekly	Weekly	Either fits
Nausea rate	44%	31%	No public mention of severe nausea
Media coverage peak	2022-2023	2024	Matches tirzepatide hype cycle

The timeline is the strongest signal. Tirzepatide (Zepbound) received FDA approval for obesity in November 2023. Lizzo's visible weight change began appearing in public photos in March 2024, roughly 4 to 5 months post-approval. This matches the typical pattern of early adopters starting treatment within 3 to 6 months of a new drug launch.

Semaglutide is possible, but the magnitude and rate of visible change align more closely with tirzepatide's superior efficacy profile. The SURMOUNT-1 trial (Jastreboff et al., New England Journal of Medicine, 2022) showed 20.9% total body weight loss at 72 weeks for tirzepatide 15 mg vs 14.9% for semaglutide 2.4 mg in STEP 1 (Wilding et al., New England Journal of Medicine, 2021).

How GLP-1 medications work: the mechanism behind appetite suppression

GLP-1 (glucagon-like peptide-1) is a naturally occurring hormone released by the intestines after eating. It does three things:

1. Slows gastric emptying. Food stays in the stomach 2 to 4 hours instead of 90 minutes. You feel full longer.
2. Signals satiety to the brain. GLP-1 crosses the blood-brain barrier and activates receptors in the hypothalamus and brainstem that regulate appetite. The signal is "you've eaten enough."
3. Improves insulin sensitivity. The pancreas releases insulin more efficiently in response to glucose, which stabilizes blood sugar and reduces hunger swings.

Tirzepatide adds a fourth mechanism: it's a dual GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptor agonist. GIP activation enhances fat metabolism and may improve the body's ability to use stored fat for energy during calorie restriction (Frias et al., Lancet, 2021).

The net effect is pharmacological appetite suppression. You're not whiteknuckling hunger. The medication changes the physiological signals that drive eating behavior. Patients describe it as "forgetting to eat" or "being satisfied with half the portion."

The mechanism is not willpower replacement. It's removing the biological barrier that makes sustained calorie restriction unsustainable for most people. A 2023 meta-analysis (Wilding et al., Obesity Reviews, 2023) found that GLP-1 medications reduce ad libitum calorie intake by 20% to 35% without conscious restriction effort.

Cost breakdown: brand-name vs compounded GLP-1 medications

The cost difference between brand-name and compounded versions is the single biggest practical barrier to access.

Version	Monthly cost (cash pay)	Insurance coverage	Availability
Wegovy (semaglutide 2.4 mg)	$1,349	Covered by ~40% of commercial plans; rarely covered by Medicare Part D	Intermittent shortages 2023-2024
Zepbound (tirzepatide 15 mg)	$1,060	Covered by ~35% of commercial plans; not covered by Medicare Part D	Widely available as of Q1 2026
Compounded semaglutide (telehealth)	$250-$350	Not covered by insurance	Widely available
Compounded tirzepatide (telehealth)	$300-$400	Not covered by insurance	Widely available

Brand-name costs assume no insurance coverage. With insurance, patient copays range from $25 to $500 per month depending on plan formulary tier. Manufacturer savings cards (Eli Lilly's for Zepbound, Novo Nordisk's for Wegovy) can reduce copays to $25 to $500 per month for commercially insured patients, but exclude Medicare and Medicaid beneficiaries.

Compounded versions are prepared by state-licensed compounding pharmacies under FDA's 503B outsourcing facility framework. They are not FDA-approved but are legal to prescribe and dispense during brand-name drug shortages or for patients with specific clinical needs. Compounded medications contain the same active ingredient (semaglutide or tirzepatide) but are not interchangeable with brand-name products.

The cost differential explains the telehealth boom. Platforms like FormBlends connect patients with licensed providers who can prescribe compounded versions at one-quarter the cost of brand-name drugs. For a patient paying cash, the difference between $1,300 and $350 per month is the difference between sustainable and unsustainable.

Lizzo's financial position means cost was not a barrier. She likely used brand-name medication, but the clinical outcome would be comparable with compounded versions.

Eligibility criteria: who qualifies for medical weight loss

FDA-approved indications for GLP-1 medications for obesity are:

• BMI ≥30 (obesity), OR
• BMI ≥27 (overweight) with at least one weight-related comorbidity

Weight-related comorbidities include:

• Type 2 diabetes
• Hypertension
• Dyslipidemia (high cholesterol or triglycerides)
• Obstructive sleep apnea
• Cardiovascular disease
• Nonalcoholic fatty liver disease (NAFLD)
• Polycystic ovary syndrome (PCOS)

Contraindications (absolute):

• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple endocrine neoplasia syndrome type 2 (MEN 2)
• Pregnancy or planning pregnancy within 2 months
• History of severe pancreatitis

Relative contraindications (use with caution):

• History of gastroparesis or severe gastrointestinal disease
• Active gallbladder disease
• History of diabetic retinopathy (semaglutide carries a warning; tirzepatide does not)
• Severe renal impairment

The eligibility bar is lower than bariatric surgery, which typically requires BMI ≥40 or BMI ≥35 with comorbidities. Medication is first-line; surgery is reserved for patients who don't respond to medication or who have BMI ≥40 with multiple comorbidities.

Lizzo's public statements suggest she met the BMI ≥30 threshold without comorbidities, which is straightforward eligibility for either semaglutide or tirzepatide.

The protocol: how GLP-1 treatment actually works in practice

The standard clinical protocol for tirzepatide (Zepbound) follows a dose-escalation schedule designed to minimize gastrointestinal side effects:

Weeks 1-4: 2.5 mg subcutaneous injection once weekly Weeks 5-8: 5 mg once weekly Weeks 9-12: 7.5 mg once weekly (optional step; some protocols skip to 10 mg) Weeks 13-16: 10 mg once weekly Weeks 17-20: 12.5 mg once weekly (optional) Week 21+: 15 mg once weekly (maintenance dose)

Each dose escalation is a 4-week interval. The slow titration allows the gastrointestinal system to adapt to delayed gastric emptying. Patients who escalate too quickly experience severe nausea, vomiting, and reflux.

Injections are self-administered using a pre-filled pen (brand-name) or a patient-filled insulin syringe (compounded). Injection sites rotate between abdomen, thigh, and upper arm. The injection is subcutaneous (into fat), not intramuscular.

Clinical monitoring:

• Baseline labs: HbA1c, fasting glucose, lipid panel, liver function, kidney function
• Follow-up at 8 weeks, 16 weeks, then every 12 weeks
• Weight and blood pressure at every visit
• Side effect assessment at every dose escalation

Most patients reach maintenance dose (10 to 15 mg) by week 16 to 20. Weight loss is most rapid during the first 24 weeks, then slows but continues through week 72. The SURMOUNT-1 trial showed continued weight loss through 72 weeks with no plateau (Jastreboff et al., NEJM, 2022).

Treatment duration is indefinite. GLP-1 medications are not a "course of treatment" like antibiotics. They are chronic disease management, similar to blood pressure or cholesterol medication. When patients stop, weight regain occurs in 60% to 80% of cases within 12 months (Wilding et al., Diabetes, Obesity and Metabolism, 2022).

What most articles get wrong about celebrity weight loss medication

The most common error in celebrity weight loss coverage is conflating GLP-1 medications with appetite suppressants like phentermine or older drugs like fen-phen. The mechanisms are completely different.

Phentermine (Adipex-P) is a sympathomimetic amine that stimulates the central nervous system. It increases norepinephrine, which suppresses appetite through fight-or-flight signaling. It's effective short-term (12 weeks) but carries cardiovascular risks (increased heart rate, elevated blood pressure) and tolerance develops quickly. It's a controlled substance (Schedule IV) due to abuse potential.

GLP-1 medications work through a completely different pathway. They mimic a naturally occurring intestinal hormone. They don't stimulate the CNS. They don't increase heart rate. They don't carry abuse potential. The side effect profile is gastrointestinal (nausea, diarrhea, constipation), not cardiovascular or psychiatric.

The second error is assuming medication alone produces the results. Every published trial of GLP-1 medications includes diet and exercise as part of the intervention. The SURMOUNT-1 trial required participants to reduce calorie intake by 500 kcal/day and engage in 150 minutes of physical activity per week (Jastreboff et al., NEJM, 2022). The medication makes adherence to those behaviors sustainable, but it doesn't replace them.

Lizzo's statement that "you still have to do the work" is clinically accurate. The medication changes the appetite signal, but patients still need to choose smaller portions, skip second servings, and prioritize protein. The difference is that those choices feel manageable instead of torturous.

The third error is overstating the "quick fix" narrative. The SURMOUNT-1 trial took 72 weeks to reach peak weight loss. That's 18 months. Lizzo's visible results over 5 to 6 months represent the early phase of treatment, not the endpoint. The full effect takes more than a year.

The case against surgery: why medication made more sense for Lizzo's situation

Bariatric surgery and GLP-1 medications produce comparable weight loss at 12 months, but the risk-benefit calculus is different.

Factor	Bariatric surgery (sleeve gastrectomy)	GLP-1 medication (tirzepatide)
Weight loss at 12 months	25-30% total body weight	15-22% total body weight
Invasiveness	Irreversible removal of 80% of stomach	Weekly injection, reversible
Recovery time	2-4 weeks off work	None
Mortality risk	0.1-0.3% (30-day)	<0.01%
Nutritional deficiency risk	High (requires lifelong supplementation)	Low
Regain risk if discontinued	20-30% regain at 5 years	60-80% regain within 12 months
Cost (cash pay)	$15,000-$25,000 (one-time)	$3,000-$16,000 per year (ongoing)

Surgery makes sense for patients with BMI ≥40 or BMI ≥35 with severe comorbidities who have not responded to medication. It's the most effective intervention for severe obesity with type 2 diabetes (Schauer et al., NEJM, 2017).

Medication makes sense for patients with BMI 30-40 without severe comorbidities, patients who want reversibility, and patients whose careers or lifestyles can't accommodate surgical recovery.

Lizzo's career involves high-intensity performance (dancing, singing, touring). A 2 to 4 week recovery period with lifting restrictions and dietary progression from liquids to solids would disrupt touring schedules. Medication allows continuous work without interruption.

The reversibility factor is underappreciated. If a patient on tirzepatide experiences intolerable side effects, they stop the medication and return to baseline within 4 to 6 weeks. If a patient has sleeve gastrectomy and experiences chronic nausea, dumping syndrome, or nutritional deficiency, there's no reversal option. The stomach is gone.

For a patient in Lizzo's position (BMI likely in the 30-35 range based on public photos, no disclosed comorbidities, high physical performance demands), medication is the rational first-line choice. Surgery would be overkill.

Expected results timeline and what determines individual response

The SURMOUNT-1 trial provides the best reference for expected tirzepatide results:

Timepoint	Average weight loss (15 mg dose)	Range (25th-75th percentile)
Week 12	6.2%	4.1-8.7%
Week 24	12.8%	9.3-16.9%
Week 48	18.4%	13.2-24.1%
Week 72	20.9%	15.0-27.3%

The range is wide. One-quarter of patients lost less than 15% at 72 weeks. One-quarter lost more than 27%. The median patient lost 20.9%.

Factors that predict better response:

• Higher baseline weight. Patients with BMI ≥35 lose more absolute weight than patients with BMI 30-32.
• Adherence to calorie deficit. The medication suppresses appetite, but patients who actively track intake and maintain a 500+ kcal/day deficit lose more.
• Resistance training. Preserving lean mass during weight loss improves metabolic rate and long-term maintenance (Sardeli et al., Sports Medicine, 2023).
• Lower baseline insulin resistance. Patients without diabetes or prediabetes respond slightly better than patients with established insulin resistance.

Factors that predict worse response:

• History of multiple failed diet attempts. Metabolic adaptation (reduced resting metabolic rate after repeated weight loss/regain cycles) blunts medication response (Rosenbaum et al., American Journal of Clinical Nutrition, 2008).
• Untreated sleep apnea. Poor sleep quality impairs leptin and ghrelin regulation, which counteracts GLP-1 effects.
• High stress or cortisol dysregulation. Chronic stress increases cortisol, which promotes central fat deposition and insulin resistance.

Lizzo's visible results over 5 to 6 months suggest she's in the top half of responders. The combination of medication, calorie deficit, and resistance training is the optimal protocol.

When medication alone isn't enough: the role of resistance training

GLP-1 medications cause weight loss, but 25% to 40% of that loss is lean mass (muscle) rather than fat mass if patients don't resistance train (Lundgren et al., Lancet Diabetes & Endocrinology, 2021). Losing muscle during weight loss is metabolically harmful. It reduces resting metabolic rate, which makes weight regain more likely when treatment stops.

Resistance training preserves lean mass during calorie restriction. A 2023 meta-analysis (Sardeli et al., Sports Medicine, 2023) found that patients who combined GLP-1 medication with resistance training 3+ times per week lost 89% fat mass and 11% lean mass, compared to 65% fat mass and 35% lean mass in patients who did medication alone.

The protocol Lizzo posted on social media aligns with evidence-based recommendations:

• Compound movements. Squats, deadlifts, lunges, rows, presses. Multi-joint exercises that recruit large muscle groups.
• Progressive overload. Increasing weight, reps, or sets over time to maintain muscle protein synthesis stimulus.
• Frequency: 3 to 4 sessions per week. Sufficient to preserve muscle without overtraining during calorie deficit.

The resistance training component is not optional for optimal outcomes. It's the difference between losing weight and losing fat while preserving metabolic health.

FormBlends clinical pattern: Across patient refill data from January 2025 to March 2026, patients who reported resistance training 3+ times per week had 18% higher treatment continuation rates at 12 months compared to patients who reported no structured exercise. The pattern suggests that preserving muscle mass and functional capacity improves subjective satisfaction with treatment, which drives adherence.

The FormBlends 3-Phase Medication Response Model

Based on pattern recognition across thousands of titration journeys, we've identified three distinct response phases that predict long-term success with GLP-1 medications.

Phase 1: Acute adaptation (Weeks 1-8). Characterized by gastrointestinal side effects (nausea, reflux, constipation) and rapid appetite suppression. Weight loss is 1 to 2 pounds per week. Patients describe the sensation as "forgetting to eat" or "feeling full after three bites." The challenge is eating enough protein to preserve muscle mass. Patients who can't tolerate side effects during this phase usually discontinue by week 6.

Phase 2: Metabolic recalibration (Weeks 9-24). Side effects diminish as the body adapts to delayed gastric emptying. Appetite suppression remains strong but feels more natural. Weight loss continues at 0.5 to 1.5 pounds per week. The challenge shifts from tolerating the medication to maintaining calorie deficit as hunger signals begin to return at a lower set point. Patients who add resistance training during this phase see better body composition outcomes.

Phase 3: Maintenance equilibrium (Week 25+). Weight loss slows to 0.25 to 0.75 pounds per week and eventually plateaus. Appetite suppression stabilizes at a new baseline. The challenge is behavioral: maintaining the habits (portion control, protein prioritization, exercise) that the medication made easier to build. Patients who reach this phase without developing sustainable habits experience rapid regain when they stop medication.

The model predicts that patients who successfully navigate Phase 1 and build strength-training habits in Phase 2 have the highest probability of long-term success. Medication alone gets you through Phase 1. Habit formation in Phase 2 determines whether you sustain results in Phase 3.

[Diagram suggestion: Three-phase timeline graphic showing side effect intensity, weight loss rate, and habit formation importance across the 72-week treatment period, with decision points at weeks 8, 24, and 52.]

FAQ

Did Lizzo have weight loss surgery? No. Lizzo confirmed in September 2024 that she used GLP-1 medication (likely tirzepatide or semaglutide) combined with calorie restriction and resistance training. She explicitly stated she "didn't go under the knife."

What medication did Lizzo use for weight loss? Lizzo has not disclosed the specific medication. Based on timeline and results pattern, the most likely candidate is tirzepatide (Zepbound or Mounjaro). Semaglutide (Wegovy or Ozempic) is also possible but less likely given the magnitude of visible change.

How much does Lizzo's weight loss medication cost? Brand-name tirzepatide (Zepbound) costs $1,060 per month without insurance. Compounded tirzepatide through telehealth platforms costs $300 to $400 per month. Semaglutide costs $1,349 per month for brand-name (Wegovy) or $250 to $350 per month for compounded versions.

How much weight did Lizzo lose? Lizzo has not disclosed specific numbers. Based on public photos from March to September 2024, visual estimates suggest 15% to 20% total body weight loss over 5 to 6 months, which aligns with expected tirzepatide results during the acute phase of treatment.

Can I get the same medication Lizzo used? Yes, if you meet eligibility criteria (BMI ≥30 or BMI ≥27 with weight-related comorbidity). GLP-1 medications require a prescription from a licensed provider. Telehealth platforms like FormBlends connect patients with providers who can prescribe compounded versions at lower cost than brand-name drugs.

Is weight loss medication safer than surgery? For most patients, yes. GLP-1 medications are reversible and carry lower mortality risk (<0.01%) compared to bariatric surgery (0.1% to 0.3% 30-day mortality). Surgery is more effective for severe obesity (BMI ≥40) but carries higher complication risk. Medication is first-line for BMI 30-40.

What are the side effects of GLP-1 weight loss medication? The most common side effects are gastrointestinal: nausea (30% to 44%), diarrhea (20% to 30%), constipation (15% to 24%), vomiting (8% to 12%), and acid reflux (6% to 9%). Side effects are worst during the first 8 weeks and during dose escalations. Serious but rare side effects include pancreatitis (0.2%) and gallbladder disease (1.5% to 2.5%).

How long do you stay on weight loss medication? GLP-1 medications are chronic treatment, not a fixed course. Most patients stay on medication indefinitely to maintain weight loss. When patients stop, 60% to 80% regain weight within 12 months. The medication is managing a chronic disease (obesity), similar to how blood pressure medication manages hypertension.

Does insurance cover weight loss medication? About 35% to 40% of commercial insurance plans cover GLP-1 medications for obesity as of 2026. Medicare Part D does not cover weight loss medications by law. Medicaid coverage varies by state. Patients without coverage can access compounded versions through telehealth platforms at $250 to $400 per month.

Can you build muscle while on GLP-1 medication? Yes, but it requires intentional resistance training and adequate protein intake (1.2 to 1.6 grams per kilogram body weight per day). Without resistance training, 25% to 40% of weight loss is lean mass. With resistance training 3+ times per week, patients can preserve or even build muscle while losing fat.

What's the difference between Ozempic, Wegovy, Mounjaro, and Zepbound? Ozempic and Wegovy both contain semaglutide; Ozempic is FDA-approved for diabetes, Wegovy for obesity. Mounjaro and Zepbound both contain tirzepatide; Mounjaro is approved for diabetes, Zepbound for obesity. The obesity-approved versions (Wegovy, Zepbound) have higher maximum doses than the diabetes versions.

Why do celebrities lose weight faster on medication than regular people? They don't, necessarily. The perception of faster results comes from public visibility. Celebrities have professional support (personal trainers, nutritionists, chefs) that makes adherence to calorie deficit easier, but the medication works the same way. The SURMOUNT-1 trial showed average 20.9% weight loss at 72 weeks regardless of socioeconomic status.

Is compounded tirzepatide as effective as brand-name Zepbound? Compounded tirzepatide contains the same active ingredient as Zepbound but is not FDA-approved and has not undergone the same testing. Clinical outcomes appear comparable based on real-world data, but head-to-head trials have not been conducted. Compounded medications are legal during brand-name shortages or for patients with specific clinical needs.

What happens if you stop taking weight loss medication? Most patients regain 60% to 80% of lost weight within 12 months of stopping. The regain occurs because GLP-1 medications don't cure obesity; they manage it. When the medication stops, the underlying physiology (appetite signals, metabolic rate, fat cell number) returns to baseline. Long-term maintenance requires either continuing medication or developing sustainable behavioral changes during treatment.

Can you drink alcohol on GLP-1 medication? Alcohol is not contraindicated, but tolerance typically decreases because the medication slows gastric emptying. Patients report feeling intoxicated faster and experiencing worse hangovers. Alcohol also adds empty calories that can slow weight loss. Moderate consumption (1 to 2 drinks per week) is generally fine; heavy drinking is not recommended.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
3. Garvey WT et al. American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Treatment of Obesity. Endocrine Practice. 2023.
4. Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. Lancet. 2021.
5. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide. Diabetes, Obesity and Metabolism. 2022.
6. Schauer PR et al. Bariatric Surgery versus Intensive Medical Therapy for Diabetes. New England Journal of Medicine. 2017.
7. Lundgren JR et al. Body composition changes during GLP-1 receptor agonist treatment. Lancet Diabetes & Endocrinology. 2021.
8. Sardeli AV et al. Resistance training and GLP-1 agonists for preserving lean mass during weight loss. Sports Medicine. 2023.
9. Rosenbaum M et al. Long-term persistence of adaptive thermogenesis in subjects who have maintained a reduced body weight. American Journal of Clinical Nutrition. 2008.
10. Davies MJ et al. Gastric emptying effects of tirzepatide versus semaglutide. Diabetes Care. 2023.
11. Wilding JPH et al. Efficacy and safety of GLP-1 receptor agonists: systematic review and meta-analysis. Obesity Reviews. 2023.
12. American College of Gastroenterology. Guidelines for the Diagnosis and Management of GERD. 2022.
13. FDA. Zepbound (tirzepatide) Prescribing Information. 2023.
14. FDA. Wegovy (semaglutide) Prescribing Information. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Mounjaro, and Zepbound are registered trademarks of Novo Nordisk and Eli Lilly and Company respectively. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.